Sionna Therapeutics, Inc.
SIONHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframePart of the healthcare sector, Sionna Therapeutics, Inc. (SION) is listed under Biotechnology. Valued at $1.65B, SION is a small-cap name in its sector. It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Market Cap
$1.65B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-13.02
EPS (TTM)
$-1.86
EPS (Fwd)
$-2.80
ROE
-26.7%
ROA
-18.3%
Cash
$216.2M
Total Debt
$8.4M
Free CF
-$45.7M
52W Change
130.9%
Annual Financials
Cash vs Debt
With $216.2M in cash and $8.4M in debt, SION maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$45.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, SION has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SION's risk profile alongside its fundamentals and technical indicators provides a more complete picture.